Ticker

Shares of Fractyl Health, Inc. (NASDAQ: GUTS - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company.

/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to

Fractyl Health (NASDAQ: GUTS) used its fourth-quarter and full-year 2025 results call to sharpen its investment narrative around Revita, its endoscopic procedure aimed at helping patients maintain weight loss after stopping GLP-1 drugs. Management said recent analyses of clinical data have clarified which patients benefit most and how procedural "dose" appears to drive outcomes, while also

Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes, today announced that it will report financial results for the fourth quarter and full year 2025 and provide business updates on Tuesday, March 24, 2026, at 4:30 p.m.